Bulto is named the chairman of the US medicines business

Swiss pharmacist Novartis has appointed company veteran Victor Bulto as head of its US pharmaceutical business, effective September 1.

He replaces Fabrice Chouraqui, who will retire in late August, Novartis said in a statement.

He gave no reason for the outage, which comes as the drug maker faces US scrutiny over handling a $ 2 million case of manipulated data linked to treatment gene therapy, Zolgensma.

He replaces Fabrice Chouraqui, who will retire in late August, Novartis said in a statement.

Bulto, who will report to Marie France Tschudin, global president of Novartis Pharmaceuticals, is a 14-year veteran of the company who has worked in all therapeutic areas of the group and helped launch several products, including medicines best-selling Cosonesex Inflammation in the US market

The statement said Chouraqui “had consistently demonstrated strong leadership, ethics and integrity” during his tenure./investing

Stay updated with INFOEUROPEFX to find out the latest news about stock market.